Severe fever with thrombocytopenia syndrome
Conditions
Interventions
Placebo group:Favipiravir tablet matching placebo
Experimental group:Favipiravir tablet (investigational product)
Sponsors
The Second Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1 .The participant or their legally authorized representative voluntarily provided written informed consent; 2. 18 years or older; 3. Suspected or confirmed severe fever with thrombocytopenia syndrome; 4. Symptom onset (fever) to hospital admission within 7 days; 5. Women of childbearing potential must agree to use highly effective contraception for 3 months after the first dose.
Exclusion criteria
Exclusion criteria: 1. Patients with severe comorbidities that significantly impair immune function or general health status, including uncontrolled cardiovascular, cerebrovascular, hepatic, renal, or hematopoietic system diseases, uncontrolled malignancies, or psychiatric disorders; 2. Patients with a history of gout, serum uric acid >540 µmol/L, or hypersensitivity to any component of the investigational product; 3. Participation in any other clinical trial within the past 3 months; 4. Patients unable to swallow oral medications; 5. Pregnant or breastfeeding women, or women planning pregnancy during the study period; 6. Any other condition deemed unsuitable for participation by the investigator;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DBV nucleic acid; | — |
Secondary
| Measure | Time frame |
|---|---|
| ICU occupancy rate;case fatality rate;Severe incidence rate; | — |
Countries
China
Contacts
Public ContactZhenhua Zhang
The Second Hospital of Anhui Medical University
Outcome results
None listed